Cardio-oncology: Gaps in knowledge, goals, advances, and educational efforts

Over the past 20 years, cancer treatments have become more effective, leading to significant improvements in survival rates. However, anticancer drugs can have several possible cardiovascular side effects; in particular, the development of left ventricular dysfunction with chemoradiation therapy can negatively affect patients’ cardiac outcome, and can limit anticancer treatments. This is an ongoing issue that will continue to persist, due to the ongoing development of new antitumor agents with potential cardiotoxic effects, and the prolonged life expectancy of long-term cancer survivors. Thus, the need for cooperation between oncologists and cardiologists in the management of cancer patients has led to the development of a new medical discipline-cardio-oncology—where the issue of cardiotoxicity is a topic of intense interest and research. However, several issues remain—the proper definition and diagnosis of cardiotoxicity, as well as monitoring and treatment strategies. In this review, the current advances in cardio-oncology, limitations of current approaches, and future research fields will be discussed.

This is a preview of subscription content, access via your institution.

Access optionsBuy single article

Instant access to the full article PDF.

39,95 €

Price includes VAT (India)

dataLayer.push({"ecommerce":{"currency":"EUR","impressions":[{"name":"Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts","id":"1534-6269","price":39.95,"brand":"Springer US","category":"Medicine & Public Health","variant":"ppv-article","quantity":1}]}});

Rent this article via DeepDyve.

function deepDyveResponse(data) { if (data.status === 'ok') { [].slice.call(document.querySelectorAll('.c-box.buybox__rent-article')).forEach(function (article) { article.style.display = 'flex' var link = article.querySelector('.deepdyve-link') if (link) { link.setAttribute('href', data.url) } }) } } var script = document.createElement('script') script.src = '//www.deepdyve.com/rental-link?docId=10.1007/s11912-017-0610-9&journal=1534-6269&fieldName=journal_doi&affiliateId=springer&format=jsonp&callback=deepDyveResponse' document.body.appendChild(script)

Learn more about Institutional subscriptions

.sprcom-buybox-articleSidebar{box-shadow: 0px 0px 5px rgba(51,51,51,0.101);display: flex;flex-wrap: wrap;font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen-Sans, Ubuntu, Cantarell, 'Helvetica Neue', sans-serif;text-align: center; } .sprcom-buybox-articleSidebar *{box-sizing: border-box;line-height: calc(100% + 4px);margin: 0px; } .sprcom-buybox-articleSidebar > *{display: flex;flex-basis: 240px;flex-direction: column;flex-grow: 1;flex-shrink: 1;margin: 0.5px; } .sprcom-buybox-articleSidebar > *{box-shadow: 0 0 0 1px rgba(204,204,204,0.494); } .sprcom-buybox-articleSidebar .c-box__body{display: flex;flex-direction: column-reverse;flex-grow: 1;justify-content: space-between;padding: 6%; } .sprcom-buybox-articleSidebar .c-box__body .buybox__buy{display: flex;flex-direction: column-reverse; } .sprcom-buybox-articleSidebar p{color: #333;font-size: 15px; } .sprcom-buybox-articleSidebar .buybox__price{font-size: 24px;font-weight: 500;line-height: calc(100% + 8px);margin: 20px 0;order: 1; } .sprcom-buybox-articleSidebar form{order: 1; } .sprcom-buybox-articleSidebar .buybox__price-info{margin-bottom: 20px; } .sprcom-buybox-articleSidebar .c-box__heading{background-color: #f0f0f0;color: #333;font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen-Sans, Ubuntu, Cantarell, 'Helvetica Neue', sans-serif;font-size: 16px;margin: 0px;padding: 10px 12px;text-align: center; } .sprcom-buybox-articleSidebar .c-box__button{background-color: #3365A4;border: 1px solid transparent;border-radius: 2px;color: #fff;cursor: pointer;display: inline-block;font-family: inherit;font-size: 16px;max-width: 222px;padding: 10px 12px;text-decoration: none;width: 100%; } .sprcom-buybox-articleSidebar h3{clip: rect(1px, 1px, 1px, 1px);height: 1px;overflow: hidden;position: absolute;width: 1px; } .sprcom-buybox-articleSidebar h2{flex-basis: 100%;margin-bottom: 16px;text-align: left; } .sprcom-buybox-articleSidebar .buybox__institutional-sub, .buybox__rent-article .c-box__body{flex-direction: row; } .sprcom-buybox-articleSidebar .buybox__institutional-sub, .buybox__rent-article .buybox__info{text-align: left; } .sprcom-buybox-articleSidebar .buybox__institutional-sub{background-color: #f0f0f0; } .sprcom-buybox-articleSidebar .visually-hidden{clip: rect(1px, 1px, 1px, 1px);height: 1px;overflow: hidden;position: absolute;width: 1px; } .sprcom-buybox-articleSidebar style{display: none; } ;(function () { var timestamp = Date.now() document.write('') var head = document.getElementsByTagName("head")[0] var script = document.createElement("script") script.type = "text/javascript" script.src = "https://buy.springer.com/assets/js/buybox-bundle-abe5f44a67.js" script.id = "ecommerce-scripts-" + timestamp head.appendChild(script) var buybox = document.querySelector("[data-id=id_"+ timestamp +"]").parentNode ;[].slice.call(buybox.querySelectorAll(".buying-option")).forEach(init) function init(buyingOption, index) { var form = buyingOption.querySelector("form") if (form) { var formAction = form.getAttribute("action") document.querySelector("#ecommerce-scripts-" + timestamp).addEventListener("load", bindModal(form, formAction, timestamp, index), false) } } function bindModal(form, formAction, timestamp, index) { var weHasBrowserSupport = window.fetch && Array.from return function() { console.log("ecommerce-scripts loaded, attempting to init modal …") var Buybox = EcommScripts ? EcommScripts.Buybox : null var Modal = EcommScripts ? EcommScripts.Modal : null if (weHasBrowserSupport && Buybox && Modal) { var modalID = "ecomm-modal_" + timestamp + "_" + index var modal = new Modal(modalID) modal.domEl.addEventListener("close", close) function close() { form.querySelector("button[type=submit]").focus() } var cartURL = "/cart" var cartModalURL = "/cart?messageOnly=1" form.setAttribute( "action", formAction.replace(cartURL, cartModalURL) ) var formSubmit = Buybox.interceptFormSubmit( Buybox.fetchFormAction(window.fetch), Buybox.triggerModalAfterAddToCartSuccess(modal), function() { form.removeEventListener("submit", formSubmit, false) form.setAttribute( "action", formAction.replace(cartModalURL, cartURL) ) form.submit() } ) form.addEventListener("submit", formSubmit, false) document.body.appendChild(modal.domEl) } else { console.log("binding failed:", weHasBrowserSupport, EcommScripts) } } } })() Fig. 1 ReferencesPapers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

DeSantis C, Lin C, Mariotto A, Siegel RL, Stein KD, Kramer JL, et al. Cancer treatment and survivorship statistics. CA Cancer J Clin. 2014;64:252–71.

Article PubMed Google Scholar

Cardinale D. A new frontier: cardioncology. Cardiologia. 1996;41:887–91.

CAS PubMed Google Scholar

Plana JC, Galderisi M, Barac, Ewer MS, Ky B, Scherrer-Crosbie M, et al. Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2014;15:1063–93.

Article PubMed PubMed Central Google Scholar

Zamorano JL, Lancellotti P, Rodriguez Muñoz D, Aboyans V, Asteggiano R, Galderisi M, et al. 2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for cancer treatments and cardiovascular toxicity of the European Society of Cardiology (ESC). Eur Heart J. 2016;37:2768–01.

Article PubMed Google Scholar

Cardinale D, Colombo A, Bacchiani G, Tedeschi I, Meroni CA, Veglia F, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131:1981–8.

CAS Article PubMed Google Scholar

Cardinale D, Biasillo G, Cipolla CM. Curing cancer, saving the heart: a challenge that cardioncology should not miss. Curr Cardiol Rep. 2016;18:51.

Article PubMed Google Scholar

•• Christenson ES, James T, Agrawal V, Park BH. Use of biomarkers for the assessment of chemotherapy-induced cardiac toxicity. Clin Biochem. 2015;48:223–35. A complete review on strength and weakness points for the use of biomarkers in the detection of cardiotoxicity

CAS Article PubMed Google Scholar

Colombo A, Sandri MT, Salvatici M, Cipolla CM, Cardinale D. Cardiac complications of chemotherapy: role of biomarkers. Curr Treat Options Cardiovasc Med. 2014;16:313.

Article PubMed Google Scholar

• Curigliano G, Cardinale D, Dent S, Criscitiello C, Aseyev O, Lenihan D, et al. Cardiotoxicity of anticancer treatments: epidemiology, detection, and management. CA Cancer J Clin. 2016;66:309–25. A complete overview on incidence, detection, prevention, management, and clinical impact of cardiotoxicity

Article PubMed Google Scholar

Lipshultz SE, Rifai N, Sallan SE, Lipsitz SR, Dalton V, Sacks DB, et al. Predictive value of cardiac troponin T in pediatric patients at risk for myocardial injury. Circulation. 1997;96:2641–8.

CAS Article PubMed Google Scholar

Cardinale D, Sandri MT, Martinoni A, Tricca A, Civelli M, Lamantia G, et al. Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy. J Am Coll Cardiol. 2000;36:517–22.

CAS Article PubMed Google Scholar

Cardinale D, Sandri MT, Martinoni A, Borghini E, Civelli M, Lamantia G, et al. Myocardial injury revealed by plasma troponin in breast cancer treated with high-dose chemotherapy. Ann Oncol. 2002;13:710–5.

CAS Article PubMed Google Scholar

Auner HW, Tinchon C, Brezinschek RI, Eibl M, Sormann S, Maizen C, et al. Monitoring of cardiac function by serum cardiac troponin T levels, ventricular repolarisation indices, and echocardiography after conditioning with fractionated total body irradiation and high-dose cyclophosphamide. Eur J Haematol. 2002;69:1–6.

CAS Article PubMed Google Scholar

Sandri MT, Cardinale D, Zorzino L, Passerini R, Lentati P, Martinoni A, et al. Minor increases in plasma troponin I predict decreased left ventricular ejection fraction after high-dose chemotherapy. Clin Chem. 2003;49:248–52.

CAS Article PubMed Google Scholar

Cardinale D, Sandri MT, Colombo A, Colombo N, Boeri M, Lamantia G, et al. Prognostic value of troponin I in cardiac risk stratification of cancer patients undergoing high-dose chemotherapy. Circulation. 2004;109:2749–54.

CAS Article PubMed Google Scholar

Specchia G, Buquicchio C, Pansini N, Di Serio F, Liso V, Pastore D, et al. Monitoring of cardiac function on the basis of serum troponin levels in patients with acute leukemia treated with anthracyclines. J Lab Clin Med. 2005;145:212–20.

CAS Article PubMed Google Scholar

Kilickap S, Barista I, Akgul E, Aytemir K, Aksoyek S, Aksoy S, et al. cTnT can be a useful marker for early detection of anthracycline cardiotoxicity. Ann Oncol. 2005;16:798–804.

CAS Article PubMed Google Scholar

Lee HS, Son CB, Shin SH, Kim YS. Clinical correlation between brain natriuretic peptide and anthracycline-induced cardiac toxicity. Cancer Res Treat. 2008;40:121–6.

Article PubMed PubMed Central Google Scholar

Cardinale D, Colombo A, Torrisi R, Sandri MT, Civelli M, Salvatici M, et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J Clin Oncol. 2010;28:3910–6.

CAS Article PubMed Google Scholar

Morris PG, Chen C, Steingart R, Fleisher M, Lin N, Moy B, et al. Troponin I and C-reactive protein are commonly detected in patients with breast cancer treated with dose-dense chemo-therapy incorporating trastuzumab and lapatinib. Clin Cancer Res. 2011;17:3490–9.

CAS Article PubMed Google Scholar

Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Cohen V, et al. Early detection and prediction of cardiotoxicity in chemotherapy-treated patients. Am J Cardiol. 2011;107:1375–80.

CAS Article PubMed PubMed Central Google Scholar

Lipshultz SE, Miller TL, Scully RE, Lipsitz SR, Rifai N, Silverman LB, et al. Changes in cardiac biomarkers during doxorubicin treatment of pediatric patients with high-risk acute lymphoblastic leukemia: associations with long-term echocardiographic outcomes. J Clin Oncol. 2012;30:1042–9.

CAS Article PubMed PubMed Central Google Scholar

• Sawaya H, Sebag IA, Plana JC, Januzzi JL, Ky B, Tan TC, et al. Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging. 2012;5:596–603. This study suggests that the combination of biomarker assessment and the newest echocardiographic techniques may have a greater value in the prediction of cardiotoxicity

Article PubMed PubMed Central Google Scholar

Geiger S, Stemmler HJ, Suhl P, Stieber P, Lange V, Baur D, et al. Anthracycline-induced cardiotoxicity: cardiac monitoring by continuous wave-Doppler ultrasound cardiac output monitoring and correlation to echocardiography. Onkologie. 2012;35:241–6.

CAS Article PubMed Google Scholar

Drafts BC, Twomley KM, D'Agostino R Jr, Lawrence J, Avis N, Ellis LR, et al. Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging. 2013;6:877–85.

Article PubMed PubMed Central Google Scholar

Mornoş C, Petrescu L. Early detection of anthracycline-mediated cardiotoxicity: the value of considering both global longitudinal left ventricular strain and twist. Can J Physiol Pharmacol. 2013;91:601–7.

Article PubMed Google Scholar

Mavinkurve-Groothuis AM, Marcus KA, Pourier M, Loonen J, Feuth T, Hoogerbrugge PM, et al. Myocardial 2D strain echocardiography and cardiac biomarkers in children during and shortly after anthracycline therapy for acute lymphoblastic leukaemia (ALL): a prospective study. Eur Heart J Cardiovasc Imaging. 2013;14:562–9.

Article PubMed Google Scholar

Ky B, Putt M, Sawaya H, French B, Januzzi JL, Sebag I, et al. Early increases in multiple biomarkers predict subsequent cardiotoxicity in patients with breast cancer treated with doxorubicin, taxanes, and trastuzumab. J Am Coll Cardiol. 2014;63:809–16.

CAS Article PubMed Google Scholar

Putt M, Hahn VS, Januzzi JL, Sawaya H, Sebag IA, Plana JC, et al. Longitudinal changes in multiple biomarkers are associated with cardiotoxicity in breast cancer patients treated with doxorubicin, taxanes, and trastuzumab. Clin Chem. 2015;61:1164–72.

CAS Article PubMed PubMed Central Google Scholar

Salvatici M, Cardinale D, Botteri E, Bagnardi V, Mauro C, Cassatella MC, et al. TnI-Ultra assay measurements in cancer patients: comparison with the conventional assay and clinical implication. Scand J Clin Lab Invest. 2014;74:385–91.

Article PubMed Google Scholar

Curigliano G, Cardinale D, Suter T, Plataniotis G, de Azambuja E, Sandri MT, et al. ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Ann Oncol 2012;23:vii155–vii166.

Soker M, Kervancioglu M. Plasma concentrations of NT-pro-BNP and cardiac troponin-I in relation to doxorubicin-induced cardiomyopathy and cardiac function in childhood malignancy. Saudi Med J. 2005;26:1197–202.

PubMed Google Scholar

Sandri MT, Salvatici M, Cardinale D, Zorzino L, Passerini R, Lentati P, et al. N-terminal pro-B-type natriuretic peptide after high-dose chemotherapy: a marker predictive of cardiac dysfunction? Clin Chem. 2005;51:1405–10.

CAS Article PubMed Google Scholar

Knobloch K, Tepe J, Lichtinghagen R, Luck HJ, Vogt PM. Simultaneous hemodynamic and serological cardiotoxicity monitoring during immunotherapy with trastuzumab. Int J Cardiol. 2008;125:113–5.

CAS Article PubMed Google Scholar

Romano S, Fratini S, Ricevuto E, Procaccini V, Stifano G, Mancini M, et al. Serial measurements of NT-proBNP are predictive of not-high-dose anthracycline cardiotoxicity in breast cancer patients. Br J Cancer. 2011;105:1663–8.

CAS Article PubMed PubMed Central Google Scholar

Dodos F, Halbsguth T, Erdmann E, Hoppe UC. Usefulness of myocardial performance index and biochemical markers for early detection of anthracycline-induced cardiotoxicity in adults. Clin Res Cardiol. 2008;97:318–26.

Article PubMed Google Scholar

Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer. 2007;7:332–44.

CAS Article PubMed Google Scholar

Thavendiranathan P, Poulin F, Lim KD, Plana JC, Woo A, Marwick TH. Use of myocardial strain imaging by echocardiography for the early detection of cardiotoxicity in patients during and after cancer chemotherapy: systematic review. J Am Coll Cardiol. 2014;63:2751–68.

Article PubMed Google Scholar

Vergaro G, Del Franco A, Giannoni A, Prontera C, Ripoli A, Barison A, et al. Galectin-3 and myocardial fibrosis in nonischemic dilated cardiomyopathy. Int J Cardiol. 2015;184:96–100.

Article PubMed Google Scholar

Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail. 2016;18:891–975.

Article PubMed Google Scholar

Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013;62:e147–239.

Article PubMed Google Scholar

Fazio S, Calmieri EA, Ferravate B, Bone F, Biondi B, Sacca L. Doxorubicin-induced cardiomyopathy treated with carvedilol. Clin Cardiol. 1998;21:777–9.

CAS Article PubMed Google Scholar

Noori A, Lindenfeld J, Wolfel E, Ferguson D, Bristow MR, Lowes BD. Beta-blockade in adriamycin-induced cardiomyopathy. J Card Fail. 2000;6:115–9.

CAS PubMed Google Scholar

Mukai Y, Yoshida T, Nakaike R, Mukai N, Iwato K, Kyo T, et al. Five cases of anthracycline-induced cardiomyopathy effectively treated with carvedilol. Intern Med. 2004;43:1087–8.

Article PubMed Google Scholar

Cardinale D, Colombo A, Lamantia G, Colombo N, Civelli M, De Giacomi G, et al. Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol. 2010;55:213–20.

CAS Article PubMed Google Scholar

Hopper I, Samuel R, Hayward C, Tonkin A, Krum H. Can medications be safely withdrawn in patients with stable chronic heart failure? Systematic review and meta-analysis. J Card Fail. 2014;20:522–32.

Article PubMed Google Scholar

Shukla A, Yusuf SW, Lenihan D, Durand J. Abstract 2942: high mortality rates are associated with withdrawal of beta blockers and ace inhibitors in chemotherapy-induced heart failure. Circulation. 2008;118:S797.

Article Google Scholar

Fadol AP, Banchs J, Hassan SA, Yeh ET, Fellman B. Withdrawal of heart failure medications in cancer survivors with chemotherapy-induced left ventricular dysfunction: a pilot study. J Card Fail. 2016;22:481–2.

Article PubMed Google Scholar

Slingerland M, Guchelaar HJ, Gelderblom H. Liposomal drug formulations in cancer therapy: 15 years along the road. Drug Discov Today. 2012;17:160–6.

CAS Article PubMed Google Scholar

FDA statement on Dexrazoxane. www.fda.gov/ Drugs/DrugSafety/ucm263729.htm.

Tebbi CK, London WB, Friedman D, Villaluna D, De Alarcon PA, Constine LS, et al. Dexrazoxane-associated risk for acute myeloid leukemia myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin’s disease. J Clin Oncol. 2007;25:493–500.

CAS Article PubMed Google Scholar

Seicean S, Seicean A, Alan N, Plana JC, Budd GT, Marwick TH. Cardioprotective effect of β-adrenoceptor blockade in patients with breast cancer undergoing chemotherapy: follow-up study of heart failure. Circ Heart Fail. 2013;6:420–6.

CAS Article PubMed Google Scholar

Kaya MG, Ozkan M, Gunebakmaz O, Akkaya H, Kaya EG, Akpek M, et al. Protective effects of nebivolol against anthracycline-induced cardiomyopathy: a randomized control study. Int J Cardiol. 2013;167:2306–10.

Article PubMed Google Scholar

Vaynblat M, Shah HR, Bhaskaran D, Ramdev G, Davis WJ 3rd, Cunningham JN Jr, et al. Simultaneous angiotensin-converting enzyme inhibition moderates ventricular dysfunction caused by doxorubicin. Eur J Heart Fail. 2002;4:583–6.

CAS Article PubMed Google Scholar

Nakamae H, Tsumura K, Terada Y, Nakane T, Nakamae M, Ohta K, et al. Notable effects of angiotensin II receptor blocker, valsartan, on acute cardiotoxic changes after standard chemotherapy with cyclophosphamide, doxorubicin, vincristine, and prednisolone. Cancer. 2005;104:2492–8.

CAS Article PubMed Google Scholar

Cadeddu C, Piras A, Mantovani G, Deidda M, Dessì M, Madeddu C, et al. Protective effects of the angiotensin II receptor blocker telmisartan on epirubicin-induced inflammation, oxidative stress, and early ventricular impairment. Am Heart J. 2010;160:487.e1–7.

Article Google Scholar

Akpek M, Ozdogru I, Sahin O, Inanc M, Dogan A, Yazici C, et al. Protective effects of spironolactone against anthracycline-induced cardiomyopathy. Eur J Heart Fail. 2015;17:81–9.

CAS Article PubMed Google Scholar

Acar Z, Kale A, Turgut M, Demircan S, Durna K, Demir S, et al. Efficiency of atorvastatin in the protection of anthracycline-induced cardiomyopathy. J Am Coll Cardiol. 2011;58:988–9.

Article PubMed Google Scholar

Seicean S, Seicean A, Plana JC, Budd GT, Marwick TH. Effect of statin therapy on the risk for incident heart failure in patients with breast cancer receiving anthracycline chemotherapy: an observational clinical cohort study. J Am Coll Cardiol. 2012;60:2384–90.

CAS Article PubMed Google Scholar

Chotenimitkhun R, D’Agostino R Jr, Lawrence JA, Hamilton CA, Jordan JH, Vasu S, et al. Chronic statin administration may attenuate early anthracycline-associated declines in left ventricular ejection function. Can J Cardiol. 2015;31:302e–7a.

Article Google Scholar

Cardinale D, Colombo A, Sandri MT, Lamantia G, Colombo N, Civelli M, et al. Prevention of high-dose chemotherapy-induced cardiotoxicity in high-risk patients by angiotensin-converting enzyme inhibition. Circulation. 2006;114:2474–81.

CAS Article PubMed Google Scholar

Ederhy S, Massard C, Dufaitre G, Balheda R, Meuleman C, Rocca CG, et al. Frequency and management of troponin I elevation in patients treated with molecular targeted therapies in phase 1 trials. Investig New Drugs. 2010;30:611–5.

Article Google Scholar

Download references

Author informationAuthors and Affiliations

Cardioncology Unit, Cardiology Department, European Institute of Oncology, Via Ripamonti 435, 20141, Milan, Italy

Gina Biasillo, Carlo M. Cipolla & Daniela Cardinale

AuthorsGina BiasilloView author publications

You can also search for this author in PubMed Google Scholar

Carlo M. CipollaView author publications

You can also search for this author in PubMed Google Scholar

Daniela CardinaleView author publications

You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Gina Biasillo.

Ethics declarations Conflict of Interest

Gina Biasillo, Carlo M. Cipolla, and Daniela Cardinale declare that they have no conflict of interest.

Human and Animal Rights and Informed Consent

This article does not contain any studies with human or animal subjects performed by any of the authors.

Additional information

This article is part of the Topical Collection on Cardio-oncology

Rights and permissions

Reprints and Permissions

About this articleCite this article

Biasillo, G., Cipolla, C.M. & Cardinale, D. Cardio-oncology: Gaps in Knowledge, Goals, Advances, and Educational Efforts. Curr Oncol Rep 19, 55 (2017). https://doi.org/10.1007/s11912-017-0610-9

Download citation

Published: 13 July 2017

DOI: https://doi.org/10.1007/s11912-017-0610-9